Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Influenza commonly referred as flu is a contagious respiratory illness caused by influenza virus. The virus can cause mild to severe illness, resulting in serious outcomes such as hospitalization or death. Geriatric population, pregnant women, and people with chronic health conditions are at high risk of serious flu complications. Influenza virus is responsible for seasonal epidemic events and are classified into two types of influenza virus, including A and B. The influenza vaccines market is expected to gain significant traction as number of manufacturers are increasing the production capacity of vaccines for use in the U.S. market for the 2017–2018 influenza season using the innovative technologies such as egg-based, cell-based, and recombinant technologies.
Market Dynamics
The major factors driving growth of the U.S. influenza vaccines market include rapid advancements in technology for development of new vaccines such as recombinant and cell-based technologies, resulting in increasing production of the vaccines. Influenza flu vaccination have the potential to reduce the risk of flu-associated hospitalization among children and adults. According to the Centers for Disease Control and Prevention, 2015, flu vaccinations prevented an around 1.9 million flu illnesses, 966,000 flu-associated medical visits, and around 67,000 flu-associated hospitalizations, representing 6.5% lowering of disease burden in the U.S. Moreover, the collaborative efforts of various government bodies such as U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) with the private sector has led to development of improved influenza vaccine technologies in the U.S. This in turn, has improved influenza pandemic preparedness in the country. Also, National Institute of Allergy and Infectious Disease (NIAID) supports research efforts to improve seasonal flu vaccine strain selection and vaccine effectiveness. However, high cost of manufacturing and complexity of the production process due to inherent variability of the viral strains are the major factors hindering growth of the U.S. influenza vaccines market.
Key features of the study:
This report provides in-depth analysis of U.S. influenza vaccines market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2016 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the U.S. influenza vaccines market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Sanofi Pasteur, Seqirus Vaccines Ltd., GlaxoSmithKline Plc., and Medimmune
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The U.S. influenza vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. influenza vaccines market
Detailed Segmentation:
U.S. Influenza Vaccines Market, By Vaccine Type:
Trivalent Vaccines
Quadrivalent Vaccines
U.S. Influenza Vaccines Market, By Virus Type:
Influenza Virus Type A
Influenza Virus Type B
U.S. Influenza Vaccines Market, By Age Group:
Pediatrics
Adults
Company Profiles
Sanofi Pasteur*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Seqirus Vaccines Ltd.
GlaxoSmithKline Plc.
Medimmune
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
? Market Definition and Scope
o Executive Summary
? Market Snippet, By Vaccine Type
? Market Snippet, By Virus Type
? Market Snippet, By Age Group
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
? Drivers
? Restraints
? Market Opportunities
? Market Trends
o Epidemiology
o PEST Analysis
o Key Highlights
o Recommendations for Nasal Spray Vaccines
o Influenza Vaccines Production Technologies
o Influenza Vaccines Approved in U.S., 2017-18 Influenza Season
o Viral Strains Prevalent in 2016-17
o Influenza Vaccine Price List
o Supply Capacity of Major Manufacturers
4. U.S. Influenza Vaccines Market, By Vaccine Type, 2017-2025, (US$ Million)
o Introduction
? Market Share Analysis, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, 2017-2025
? Segment Trends
o Trivalent Vaccines
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017-2025, (US$ Million)
o Quadrivalent Vaccines
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017-2025, (US$ Million)
5. U.S. Influenza Vaccines Market, By Virus Type, 2017-2025, (US$ Million)
o Introduction
? Market Share Analysis, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, 2017-2025
? Segment Trends
o Influenza Virus Type A
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017-2025, (US$ Million)
o Influenza Virus Type B
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017-2025, (US$ Million)
6. U.S. Influenza Vaccines Market, By Age Group, 2017-2025, (US$ Million)
o Introduction
? Market Share Analysis, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, 2017-2025
? Segment Trends
o Pediatrics
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017-2025, (US$ Million)
o Adults
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017-2025, (US$ Million)
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis (3x3 Matrix)
o Company Profiles
? Sanofi Pasteur*
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Seqirus Vaccines Ltd.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? GlaxoSmithKline Plc
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Medimmune
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
o Analyst Views
8. Section
o References
o Research Methodology
o About us and Sales Contact
*Browse 20 market data tables and 15 figures on "U.S. Influenza Vaccines Market - forecast to 2025".
